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Abstract
Background: Rhabdomyosarcoma (RMS) is a malignant tumor of mesenchymal origin and comprises the largest
category of soft-tissue sarcomas both in children and adolescents. From a pediatric oncology point of view, RMS
has traditionally been classified into alveolar (ARMS) and embryonal (ERMS) subtypes. The anatomical localization of
the tumor may vary, but commonly involve the head/neck regions, male and female urogenital tract or the trunk
and extremities.
Case presentation: Here, we report two challenging cases involving 17- and 9-years-olds males where diffuse and
multiplex bone lesions suggested either a hematological disease or a primary bone tumor (mesenchymal
chondrosarcoma). Biopsies, proved a massive infiltration of the bone marrow cavity with rhabdomyosarcoma.
In both cases, the ARMS subtype was confirmed using FOXO1 break-apart probes (FISH). Radiological examination
could not identify primary soft tissue component in any localization at the time of diagnosis in either cases.
Conclusions: Primary alveolar rhabdomyosarcoma of the bone as a subtype of ARMS, seems to be a distinct clinico-
pathological entity with challenging diagnostic difficulties and different, yet better, biological behavior in comparison
to soft tissue ARMS. However, it is difficult to be characterized or predict its prognosis and long-term survival as only
sporadic cases (four) were reported so far.
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Background
Rhabdomyosarcoma (RMS) is among the most common
soft tissue sarcomas in childhood and adolescence with
4.5 new cases/1 million person/year in the USA and in-
cidences in Europe share similar numbers [1, 2]. It is a
high-grade malignancy that primarily involves the head
and neck region, the urogenital tract or may develop in
soft tissues of the trunk or extremities. Histologically,
RMS is comprised of four subtypes; among which em-
bryonal and alveolar RMSs are the most common ones
under the age of 20, while pleomorphic and spindle cell
variants of the tumor may also occur in adults, with a
peak at the 4th-5th and 6th -7th decades of lifetime,
respectively. RMS is a high-grade malignancy and the
subtype determines the prognosis of the disease. While
embryonal RMS has a better outcome (5-year survival
rate of 82 %), the alveolar variant of the tumor has a
worse prognosis (5-year survival rate of 65 %) which is
presumably associated with the cytogenetic aberrations
this latter subtype carry [3, 4]. Alveolar RMS can be
characterized by a recurrent cytogenetic alteration in-
volving FOXO-1 and PAX3 or PAX7 genes, and the con-
secutive translocations (t(2;13) or t(1;13) respectively)
lead to the excess synthesis of fusion proteins with onco-
genic effects [5, 6].
Available data about primary bone ARMS is limited
due to the fact that so far only four cases were found in
literature reporting fusion-positive alveolar RMS con-
fined to the bone marrow [7–10]. Thus, it is difficult to
predict the disease course, the biological behavior and
its characteristics. Nonetheless, according to these re-
ports as well as our experiences, primary bone ARMS
seems to have a better prognosis and survival rate com-
pared to its soft tissue counterpart. Here we report two
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further cases of primary ARMS of the bone that posed a
diagnostic challenge both from a clinical as well as a
pathological point of view.
Case presentations
Clinical findings of Case 1
A 17-year-old male with Crohn’s disease in his medical
history, presented with fever, weight loss and lower back
pain; experienced over a period of 1–2 weeks. He was
found to have elevated inflammatory markers and ser-
ious hypercalcemia with impaired renal function. Bone
scintigraphy, lumbar spine and pelvic MRI revealed dis-
seminated, diffuse infiltration of the bone marrow which
primarily raised the suspicion of lymphoma (Fig. 1a). Re-
peated bone marrow biopsies (iliac crests) confirmed
ARMS (Grade III). A primary soft tissue tumor was
never found. During chemotherapy according to CWS-
2012 Protocol’s metastatic arm, dose reduction and
modifications of cytostatic drugs, intensive care and
hemodialysis were required several times due to serious
arrhythmias and renal insufficiency caused by osteolysis-
induced hypercalcemia. Despite the appropriate, aggres-
sive chemotherapy, his disease showed progression that
could be delayed temporarily by RANKL inhibitor deno-
sumab monotherapy for a four month period. We lost
him seven months after the initial symptoms.
Pathological findings of Case 1
Histological examination of the second bone marrow bi-
opsy (iliac crests) revealed solid sheets of tumor cells in-
filtrating the entire bone marrow replacing and expelling
the normal hematopoietic cells. The highly cellular infil-
trate showed no special arrangement, although fine
fibro-vascular stroma could focally be identified. The
monomorphic, poorly differentiated tumor cells had
round, vesicular nuclei with fine chromatin content and
were localized at the periphery of the cells, in an eccen-
tric position (Fig. 1b). The cytoplasm of most of the
tumor cells possessed either an eosinophilic appearance
or abundant intracytoplasmic vacuoles could be seen.
While tumor cells did not show striation, the overall
morphology suggested rhabdomyoblast-like differenti-
ation (Fig. 1b). Although, by examining a HE specimen,
a hematological malignancy could be ruled out, further
immunohistochemical (IHC) tests were needed to
characterize the phenotype of the tumor cells. The re-
sults of IHC showed diffuse vimentin positivity as well
as the cells gave substantial cytoplasmic and nuclear la-
belling with both rhabdomyogen markers, desmin and
Myf-4, respectively (Fig. 2a–c). The pan-cytokeratin and
TFE-3 reactions were negative as well as INI-1 was
retrained; by which alveolar soft part sarcoma or rhab-
doid tumor as a differential diagnostic possibility could
be ruled out. As the overall pattern of the tumor was
not typical for neither embryonal nor alveolar RMS, we
further performed a FOXO-1 break-apart FISH probe as
the aforementioned gene is known to be involved and is
consistently associated with the alveolar subtype of
RMS. Indeed, we detected the translocation and break-
apart signals involving FOXO-1 (Fig. 2d). Based on the
histological and molecular findings as well as extended
radiological examinations not proving a primary soft
tissue tumor, the diagnosis of primary ARMS (solid vari-
ant) of the bone was made.
Clinical background of Case 2
A 9-year-old male was admitted to the hospital pre-
sented with recurrent fever, lower back and right lower
limb pain, experienced over the period of a month. He
was found to have mild anemia and elevated inflamma-
tory markers. Imaging studies revealed disseminated
multiplex bone lesions involving the entire vertebral col-
umn, pelvic bones, ribs, skull, the distal part of the right
femur and the proximal part of the right tibia (Fig. 3a).
These findings and the lack of primary soft tissue mani-
festation raised the possibility of Ewing-sarcoma or
Fig. 1 Radiological image and hematoxylin-eosin stained specimen of the tumor. a Axial T2 SPAIR image of pelvis shows diffuse patchy infiltration
(arrowheads) of the bone marrow. Some small necrotic areas are also visible. b The HE stained biopsy sample shows highly cellular infiltrate among
the bony trabeculae repelling the normal hematopoietic cells (insert image). With higher magnification, the monomorphic tumor cells have a
characteristic eosinophilic cytoplasm, however tumor cells also show intracytoplasmic vacuolization (arrowheads). The nuclei of tumor cells are
eccentric in position, but rather identical in size and own a finely granulated, basophilic nuclear structure (arrows). Note that the organization
of tumor cells represent a somewhat nest-like pattern, but lack fine fibrovascular stroma, that is characteristic of the solid variant of alveolar
RMS. Bars indicate 50 μm, insert 100 μm
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malignant lymphoproliferative disease. Initially, the pa-
tient required intensive therapy for serious hypercalce-
mia and its complications due to osteolysis. The initial
histological diagnosis was mesenchymal chondrosar-
coma (Grade III), but the atypical clinical findings made
histological revision necessary which, in turn, confirmed
alveolar rhabdomyosarcoma with bone marrow involve-
ment. A primary soft tissue tumor could not be identi-
fied. The therapeutic response was excellent in relation
to the first-line chemotherapy given according to CWS-
2009 Protocol’s metastatic arm as control MRI and PET/
CT revealed complete remission. Seven months after fin-
ishing the first-line therapy, a relapse of the primary dis-
ease was confirmed, localized to the distal femur and
proximal tibia on the right side. Second-line therapy was
given according to CWS-2012 relapse protocol and
based on the proven ALK-positivity of the tumor, ALK
inhibitor crizotinib was permitted as an off-label drug
for maintenance therapy for 10 months. In the fourth
month of crizotinib treatment multiplex metastases were
confirmed. Based on the proven increased mTOR activ-
ity of the previous biopsy specimen (iliac crests), mTOR
inhibitor temsirolimus was given for 3 months. Due to
disease progression, both targeted therapies were
stopped and 30 months after the primary diagnosis, we
lost the patient.
Pathological findings of Case 2
The biopsy sample that was taken from the tibia showed
different morphological patterns and areas that made
the overall histological picture misleading: among the
bony trabeculae, a cellular tumor infiltrate could be
identified and the cells were arranged in solid sheets re-
placing the normal hematopoiesis. Other foci of the
tumor showed intramedullary cartilage islands around
which spindle or ovoid shape tumor cells formed a cohe-
sive structure; allowing mesenchymal chondrosarcoma
diagnosis. Besides this, however, some areas of the
tumor formed solid sheets of tumor islands that were
divided by fine fibro-vascular stroma (Fig. 3b–d). The
cytomorphology was identical with a so called “small
round blue cell tumor”. Considering that neither the age
nor the dissemination of the process (multiplex bony le-
sions) were typical for mesenchymal chondrosarcoma,
we further evaluated the phenotype of the tumor cells
with several IHC tests. The cells showed cytoplasmic
positivity with vimentin as well as intensive and diffuse
cytoplasmic desmin and nuclear Myf-4 reactions being
observed (Fig. 3e–f ). To further characterize the subtype
of RMS without an identifiable soft tissue component,
we performed a FOXO-1 break apart FISH DNA probe
that evaluated the translocation involving FOXO-1. Con-
cerning the clinical and pathological findings, the final
diagnosis of primary alveolar rhabdomyosarcoma of the
bone was made.
Discussion
Alveolar rhabdomyosarcoma is a high grade neoplasm
that has the worst prognosis amongst other subtypes of
RMSs (despite combined surgical and chemo/radiother-
apy), especially in fusion-positive cases when FOXO-1
gene is involved. It is generally known that the overall
outcomes for patients with soft tissue ARMS is worse
than in patients with ERMS - even with aggressive
multimodal therapy [4]. The prognostic factors defining
the outcome of patients with RMS includes the follow-
ing parameters: patient’s age, site of origin, tumor size,
resectability, presence of metastases, number of meta-
static sites or tissues involved, presence or absence of
regional lymph node involvement, delivery of radiation
therapy in selected cases, the unique biological charac-
teristics of RMS tumor cells and, lastly the histological
subtype. [11–14]. Regarding the histopathological sub-
type, there is a significant difference between the 5-year
survival with ERMS (82 %) and soft tissue ARMS (65 %)
[4]. Besides this, patients with (soft tissue) ARMS who
have regional lymph node involvement face a worse out-
come (5-year failure-free survival: 43 %) as compared to
patients lacking lymph node involvement (5-year failure-
free survival: 73 %) [15].
Although the previously reported four cases of primary
ARMS (as well as our current two cases) show a better
survival rate compared to its soft tissue counterpart, it
still causes difficulties in precisely characterizing this
tumor type. One reason is the low number of reported
Fig. 2 Immunohistochemical and molecular characterization of tumor
cells. a Tumor cells show diffuse vimentin positivity, as well as diffuse
and strong cytoplasmic and nuclear labelling could be observed with
myogenic markers desmin and Myf-4, respectively (b–c). The result
of FOXO-1 gene break-apart FISH probe demonstrates divided green
and red signals indicating translocation of the affected gene (d). Bars
indicate: 50 μm
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cases, while a major problem alongside this is that even
data contained within medical literature is confusing
with regards to ARMS classification. It distinguishes
fusion-positive and fusion-negative cases; however, there
is a tendency that fusion-negative cases should be con-
sidered in practical terms ERMS [16]. Until this ten-
dency is not generalized and accepted in routine
diagnostic pathology, there will be cases influencing and
altering the results exhibited in statistics.
In the case of (soft tissue) alveolar RMS it is known
that it commonly infiltrates the bone marrow [17], caus-
ing a diagnostic challenge (both in childhood and adult
cases), as it can mimic the symptoms of either a
hematological malignancy or a primary bone tumor;
therefore, biopsy sampling is necessary in each and every
case. The most common differential diagnostic problems
(considering the localization and/or age) are as follows:
Ewing sarcoma, non-Hodgkin lymphoma, mesenchymal
Fig. 3 Radiological image and histopathology of Case 2. a On the axial T2 SPAIR image of the pelvic bone multiple, partially coalesced tumor nodules
are visible in the bone marrow. Some of them (arrowheads) show central necrosis. b There were foci of tumor islands with atypical chondrogenic
differentiation surrounded by round/spindle shape tumor cells. c–d Besides that, expansive sheet like pattern with solid nests could also be identified
that were divided by fine fibrovascular septa. The infiltrate displaced the normal hematopoiesis of the bone marrow. e–f The diffuse and intensive
cytoplasmic desmin and nuclear Myf-4 positivity proved rhabdomyosarcoma differentiation of tumor cells. Bars indicate: 50 μm
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chondrosarcoma and the small cell variant of osteosar-
coma. While the morphology of tumor cells are similar
(small, round cells), the pattern of infiltration or the ac-
companying component of the tumor (neoplastic osteoid
or hyaline cartilage in small cell variant of OS and mesen-
chymal chondrosarcoma, respectively) as well as special
cytomorphological features such as intracytoplasmic vacu-
oles or striation of the tumor cells (like in RMS) may
sometimes suggest the differentiation lineage. Besides the
careful examination of HE stained samples and morpho-
logical analysis, ancillary techniques are essential in these
cases in order to give a definitive diagnosis. The combin-
ation of IHC tests including LCA, vimentin, desmin and
CD99 is useful to primarily assess the phenotype of the
tumor cells. Although IHC evaluation is sufficient and
may lead to a final diagnosis, in most of the cases further
molecular examinations such as flow cytometry (especially
in hematological diseases) or genetic analysis with regard
to gene fusion status (e.g. in Ewing sarcoma and ARMS)
are now part of the routine diagnostic panel [18, 19].
The natural history of primary alveolar RMS of bone
may show individual variations, but our current cases,
together with the other four reported ones [7–10], sug-
gest a better overall prognosis as compared to soft tissue
ARMS (Table 1). Primary alveolar rhabdomyosarcoma of
the bone as a subtype of ARMS seems to be a distinct
clinico-pathological entity. We wish to stimulate the sci-
entific community into publishing and following-up
similar cases. With this proposal, there might be more
available data to predict not only the biological behavior
and prognosis of the disease, but also to develop and set
up further chemotherapeutical combinations that may
increase the overall survival of the patients in the future.
Conclusion
Primary alveolar rhabdomyosarcoma of the bone as a
subtype of ARMS, seems to be a distinct clinico-
pathological entity with challenging diagnostic difficul-
ties and different biological behavior when compared to
soft tissue ARMS. More available data might be neces-
sary to predict not only the course of the disease, but
also to develop and set up further chemotherapeutical
combinations that may increase the overall survival of
the patients in the future.
Table 1 Reported cases of primary alveolar rhabdomyosarcoma of the bone so far without identifiable soft tissue component
Case Reference Age Sex Follow-up/survival
(months)
Treatment Tumor localization
1 Yamaguchi et al. 2007 [9] 14 m 8 (s) -Etoposide Disseminated BM infiltration, not specified
-Cyclophosphamide
-Pirarubicin
-Cisplatin
-Vincristine
2 Jani et al. (2009) [7] 16 m 8 (s) -VP16 Disseminated BM infiltration, not specified
-Ifosfamide
-Vincristine
-Adriamycin
-Cyclophosphamide
3 Kern et al. (2015) [10] 52 f 12 (s) Not detailed BM infiltration, not specified
4 Karagiannis et al. (2015) [8] 61 f 7 (f) -Topotecan BM infiltration, not specified
-Cyclophosphamide
-Vinorelbine (Monotherapy-later)
5 Case 1 (current report) 17 m 7 (s) -Ifosfamid Diffuse BM infiltration
-Carboplatin
-Etoposid
-Vincristin
6 Case 2 (current report) 9 m 30 (s) -Ifosfamid Tibia, femur, pelvic bones, vertebrae
-Etoposid
-Carboplatin
-Topotecan
The subtype has been evaluated in each case with molecular diagnostic tools (FISH, Sanger sequencing, spectral karyotyping, cytogenetics)
BM bone marrow, s survival, f follow-up
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